<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             J Immunol. 2013 March 1; 190(5): 2138&#226;&#8364;&#8220;2149. doi:10.4049/jimmunol.1202801. <br />  <br />  <br />  <br />                            Live Attenuated Leishmania donovani p27 Gene Knockout <br />                            Parasites Non-pathogenic Elicit Long Term Protective <br />                            Immunity BALB/c Mice <br />                            Ranadhir Dey*,&#194;&#182;, Pradeep K. Dagur&#194;&#182;&#194;&#182;, Angamuthu Selvapandiyan#, J. Philip McCoy&#194;&#182;&#194;&#182;, <br />                            Poonam Salotra##, Robert Duncan*, Hira L. Nakhasi*,&#194;&#182; <br />                            *Division Emerging Transfusion Transmitted Diseases, Center Biologics Evaluation  <br />                            Research, Food Drug Administration, Bethesda, Maryland, 20892. USA <br />                            &#194;&#182;&#194;&#182;FlowCytometry Core, National Heart, Lung, Blood Institute, National Institutes Health, <br />                            Bethesda, MD 20892, USA <br />                            #InfectiousDiseases, Institute Molecular Medicine, 254, Okhla Industrial Estate, Phase III, New <br />                            Delhi, 110020 India <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            ##Institute   Pathology, Indian Council Medical Research, New Delhi, 110029 India <br />  <br />                            Abstract <br />                                  Leishmaniasis causes significant morbidity mortality worldwide vaccines <br />                                  available disease. Previously, shown amastigote specific protein p27 <br />                                  (Ldp27) component active cytochrome c oxidase complex L. donovani                                  deletion gene parasite reduced virulence vivo. study, shown                                  Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites survive 20 weeks BALB/c mice, safe                                  immunogen. virulent challenge, 12 weeks post-immunized mice showed significantly lower <br />                                  parasite burden liver spleen. mice challenged 20 weeks post immunization, <br />                                  significant reduction parasite burden suggesting long term protection                                  Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization. Immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; induced pro- anti- inflammatory <br />                                  cytokine responses activated splenocytes enhanced leishmaniacidal activity association <br />                                  production. Protection short long term immunized mice challenge                                  wild type parasite correlated stimulation multifunctional Th1 type CD4 CD8 T <br />                                  cells. Adoptive transfer T cells long term immunized mice conferred protection NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  virulent challenge na&#195;&#175;ve recipient mice suggesting involvement memory T cell response                                  protection Leishmania infection. Immunization mice Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217;                                  demonstrated cross-protection Leishmania major Leishmania braziliensis <br />                                  infection. data genetically modified live attenuated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites safe, <br />                                  induce protective immunity absence parasites provide protection                                  homologous heterologous Leishmania species. <br />  <br />  <br />                            Introduction <br />                                             Leishmaniasis insect vector borne disease caused protozoan parasite <br />                                             Leishmania. Approximately 350 million people worldwide living tropical subtropical <br />                                             regions threat infections. 12 million infections worldwide <br />  <br />                            &#194;&#182; <br />                             correspondence addressed: Hira L. Nakhasi, Ph.D., Phone: 301 827 3008, Fax: 301 480 7928, <br />                            Hira.Nakhasi@fda.hhs.gov. Ranadhir Dey, Ph.D., Phone: 301 827 2055, Fax: 301 480 7928, Ranadhir.Dey@fda.hhs.gov. <br />                            Findings study informal communication represent authors best judgment. comments bind                            obligate FDA. <br />                             Dey et al.                                                                                           Page 2 <br />  <br />  <br />                                         ~2 million new clinical cases reported annually estimated death toll ~50,000 <br />                                         persons/year (1). clinical manifestation leishmaniasis depends infecting <br />                                         Leishmania species host factors range mild cutaneous leishmaniasis <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         (CL) potentially fatal visceral leishmaniasis (VL) (2&#226;&#8364;&#8220;4). VL major health <br />                                         problems Indian subcontinent, East Africa Latin American countries <br />                                         (5&#226;&#8364;&#8220;7). Available drugs toxic, emergence drug resistant parasites                                         infection HIV make drug treatment regime complex (8). Currently <br />                                         vaccines Leishmania infections human. leishmaniasis, host <br />                                         defense intracellular Leishmania cell mediated, involves Th1 responses                                         T-cells primed dendritic macrophage cells producing 12 (9&#226;&#8364;&#8220;12). <br />                                         Production 12 antigen presenting cells IFN&#206;&#179; T cells crucial                                         controlling parasite growth enhancing <span id='am-18' about='obo:IMR_0100128' typeof='owl:Thing obo:IMR_0001720 obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0000001'><span id='am-19' property="oboInOwl:hasDbXref" content="KEGG:C00533" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasAlternativeId" content="IMR:0200407" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:id" content="IMR:0100128" datatype="xsd:string"></span><span id='am-23' property="rdfs:label" content="nitric oxide" datatype="xsd:string"></span><span id='am-24' property="rdfs:label" content="Nitrogen monoxide" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasExactSynonym" content="Nitrogen monoxide" datatype="xsd:string"></span>nitric oxide</span> generation (13). Th2 <br />                                         cytokines, mainly 10, suppress host immunity help parasite survival (13&#226;&#8364;&#8220;14), <br />                                         10 protects host tissue damage excessive inflammatory <br />                                         cytokines (15). Unlike cutaneous leishmaniasis, Th1/Th2 dichotomy clear                                         visceral infection mice human VL (16). immune response                                         pathology visceral leishmaniasis complex involving number genetic cellular <br />                                         factors process susceptibility resistance parasites (17). <br />  <br />                                         past years, approaches tested Leishmania vaccine development <br />                                         DNA vaccination, subunit vaccination heat killed parasite vaccination NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         adjuvant (8, 18&#226;&#8364;&#8220;19). worked animal models                                         successful far humans. Leishmanization, process deliberate infections <br />                                         Leishmania major cause controlled skin lesion low number parasites                                         shown provide protection reinfection (20&#226;&#8364;&#8220;21). Immunity                                         acquired pre-exposure infection demonstrated individuals migrated <br />                                         L. major endemic region reactive Leishmania antigen, lower risk <br />                                         developing VL (22&#226;&#8364;&#8220;23).  studies suggest effective vaccine <br />                                         leishmaniasis controlled parasitic infection provide complete array                                         antigens wild type parasite necessary developing protective immune <br />                                         response. Past experience pathogens suggested live attenuated pathogens <br />                                         fulfill requirement (24&#226;&#8364;&#8220;26) <br />  <br />                                         Attempts develop live attenuated Leishmania vaccine, including <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>chemical</span> mutagenesis, <br />                                         long-term serial vitro cultures, irradiation, temperature sensitivity targeted gene <br />                                         deletions alleles past (18, 27&#226;&#8364;&#8220;33).                                          mutated parasite cell lines developed species causing cutaneous leishmaniasis,                                         L. major L. mexicana. Attempts using partial targeted gene deleted <br />                                         parasites A2-A2rel gene cluster L. donovani (34) SIR2 gene L. infantum <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         (35) test immunogens.  mutants developed VL causing parasites <br />                                         used vaccine candidates carry single alleles wild type <br />                                         gene revert wild genotype regain virulence. critical                                         develop attenuated parasites complete gene knockouts alleles                                         virulence gene non-functional capable reversion cause disease. L. <br />                                         donovani biopterin transporter (BT1) null mutant parasites alleles disrupted                                         tested mice showing reduced infectivity induced protection infection                                         wild type parasites (36). study did address issue safety                                         correlates immune protection genetically modified live attenuated L. donovani <br />                                         parasites. address question, previously developed amastigote specific <br />                                         replication deficient Centrin gene deleted L. donovani parasite cell line (LdCen&#226;&#710;&#8217;/&#226;&#710;&#8217;)                                         tested rodent model, limited persistence induce protective <br />                                         cellular immune response immunized animals (37). Recently, developed L. <br />                                         donovani cell line devoid p27 gene, encoding amastigote specific cytochrome c <br />  <br />  <br />                                              J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                              Page 3 <br />  <br />  <br />                                          oxidase component (38) demonstrated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites persist longer (&gt; 12 <br />                                          weeks) compared LdCen&#226;&#710;&#8217;/&#226;&#710;&#8217; (5 weeks) mice (37&#226;&#8364;&#8220;38). evaluated                                          longer persistence Leishmania antigens produce better protection. current study <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          showed Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite cell line, persist extended period                                          time causing pathogenesis, elicit effective cell mediated effector protective <br />                                          immune response homologous heterologous Leishmania species. <br />  <br />                               Materials Methods <br />                               Animals parasites <br />                                          week old female BALB/c mice National Cancer Institute, Bethesda, MD <br />                                          used experiments. Procedures used reviewed approved Animal <br />                                          Care Use Committee, Center Biologics Evaluation Research, Food Drug <br />                                          Administration. parasites, wild type (Wt) L. donovani (Ld1S) maintained                                          Golden Syrian hamsters p27 gene deleted (Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217;) L. donovani (Ld1S2D) (38) <br />                                          used. parasites cultured according procedure previously described (39&#226;&#8364;&#8220; <br />                                          40). Leishmania major (Friedlin) L. braziliensis promastigotes grown 26&#194;&#176;C                                          medium 199 supplemented (M199/S) 20% fetal calf serum. <br />  <br />                               Immunizations challenge studies <br />                                          mice immunized tail vein 3 &#195;&#8212; 106 stationary phase Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites. NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          study 4 5 mice used group. Immunized mice challenged different <br />                                          time periods immunization tail vein 105 stationary phase Wt L. donovani <br />                                          parasites. Age matched na&#195;&#175;ve mice controls similarly challenged 105 <br />                                          virulent stationary phase Wt L. donovani parasites. separate experiments, mice <br />                                          immunized  Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217;) (na&#195;&#175;ve saline) challenged injecting s. <br />                                          c./  d. left hind footpad 105 stationary phase L. major 106 stationary phase L. <br />                                          braziliensis parasites. various periods post challenge, parasite load measured                                          spleens livers L. donovani challenged mice footpads lymph <br />                                          nodes L. major L. braziliensis challenged mice limiting dilutions                                          previously described (41). additional confirmation presence parasites                                          tissues, total DNA obtained spleens mice certain groups specified                                          results used template real-time PCR. real-time PCR based                                          target kinetoplast minicircle DNA using primers methods described (42). <br />  <br />                                          immune-suppression study, mice infected Wt Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites, <br />                                          20 weeks 25 weeks post-infection 2 mg/kg Dexamethasone sodium phosphate (Sigma <br />                                          Aldrich) PBS administered subcutaneously 3 times week (43). end NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          treatment mice sacrificed evaluated parasite burden visceral organs. <br />  <br />                               Multiplex Cytokine ELISA <br />                                          Single cell suspensions prepared splenocytes lysis red blood cells                                          using Ammonium-Chloride-Potassium (ACK) lysing buffer (Lonza, MD, USA). Cells                                          washed medium plated 24 plates stimulated freeze-thaw L. <br />                                          donovani antigen (FTAg) Ag complete RPMI 1640 medium 37&#194;&#176;C 5% <br />                                          <span id='am-12' about='obo:IMR_0200324' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-13' property="oboInOwl:hasDbXref" content="KEGG:C00011" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0200324" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-16' property="rdfs:label" content="CO2" datatype="xsd:string"></span>CO2</span> 95% humidity incubator. 72 hours culture cell supernatants                                          collected stored &#226;&#710;&#8217;80&#194;&#176;C analyzed using multiplex kits, Milliplex Mouse <br />                                          Cytokine/ Chemokine Magnetic Panel Millipore, USA plate read                                          Luminex -100&#226;&#8222;&#162; (Luminex, Austin, USA) using Bioplex manager software 5.0.                                          cytokine analysis procedure performed according manufacturer&#226;&#8364;&#8482;s instructions <br />                                          level cytokine concentration determined using standard curve                                          specific cytokine. <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                           Page 4 <br />  <br />  <br />                               Intracellular staining flow cytometry <br />                                           Splenocytes plated 24 plates complete RPMI medium 37&#194;&#176;C                                           stimulated FTAg (80&#206;&#188;g/ml) (44). 48 hrs 37&#194;&#176;C Protein Transport <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Inhibitor (BD Golgi Stop, BD Pharmingen) added wells. hours cells <br />                                           blocked 4&#194;&#176;C Rat anti mouse CD16/32 (5&#206;&#188;g/ml) BD Pharmingen 20 <br />                                           minutes. Cells surface stained anti mouse CD3 APC-eFluor@780, anti mouse <br />                                           CD4 eFluor@450, anti mouse CD8a eFluor@605NC, anti mouse CD44 FITC, anti <br />                                           mouse CCR7 PE-Cy5 antibodies (eBioscience, USA) 30 min  1:200 dilution; <br />                                           4&#194;&#176;C). cells stained Live/Dead Fixable Aqua (Invitrogen, Molecular <br />                                           Probes) stain dead cells. Cells washed wash buffer fixed Cytofix/ <br />                                           Cytoperm kit (BD Bioscience) 20 min (room temperature). Intracellular staining                                           anti mouse IFN&#206;&#179; PE-Cy7, anti mouse TNF&#206;&#177; PerCp-eFluor@710, anti mouse 2 <br />                                           APC anti mouse 10 PE (eBioscience, USA) 30 min  1:300 dilution; <br />                                           4&#194;&#176;C). Cells acquired LSRII (BD Biosciences, USA) equipped 405, 488, 532, <br />                                           638 laser lines using DIVA 6.1.2 software. Data analyzed FlowJo <br />                                           software version 9.1.5 (Treestar, San Carlos, CA). analysis, doublets removed <br />                                           using width parameter; dead cells excluded based staining Live/Dead Aqua <br />                                           dye. Lymphocytes identified according light-scattering properties. CD4                                           CD8 T-cells identified CD3+ lymphocytes uniquely expressing CD4 CD8. <br />                                           gating intracellular cytokines measured CD44Hi CCR7Low cells. FMO <br />                                           controls used proper gating positive events designated cytokines. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Antibody responses <br />                                           Specific antibody responses measured conventional enzyme-linked <br />                                           immunoadsorbent assay (ELISA). Briefly, ELISA plates coated overnight room <br />                                           temperature FTAg (15&#206;&#188;g/ml). serial dilution sera carried determine <br />                                           titer, defined inverse highest serum dilution factor giving                                           absorbance &gt;0.2. titers antibodies determined using following <br />                                           horseradish peroxidase-conjugated secondary antibodies: Rabbit anti-mouse IgG (<span id='am-26' about='obo:IMR_0200030' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-27' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-28' property="rdfs:label" content="H+" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasDbXref" content="KEGG:C00080" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:id" content="IMR:0200030" datatype="xsd:string"></span>H</span>+L)- <br />                                           HRP; Rabbit anti-mouse IgG1-HRP, Rabbit anti-mouse IgG2a-HRP; Southern Biotech, <br />                                           Birmingham, AL; 1:1000 dilutions). SureBlue&#226;&#8222;&#162; (KPL, Gaithersburg, MD) used <br />                                           peroxidase substrate. 15 min, reaction stopped addition 100 &#206;&#188;l <br />                                           1M H2SO4, absorbance read 450 nm. <br />  <br />                               Histological staining <br />                                           Mouse livers fixed fixative solutions (10% buffered formalin phosphate solution), <br />                                           sent Histoserv, Gaithersburg, MD USA sectioning H<span id='am-5' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-6' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-8' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-11' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span>amp</span>;E staining. Stained <br />                                           sections analyzed microscope (Nikon Eclipse TE2000-U). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               quantification <br />                                           Splenocytes macrophages obtained peritoneal fluid (45) cultured complete <br />                                           RPMI medium presence absence FTAg 24 <span id='am-26' about='obo:IMR_0200030' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-27' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-28' property="rdfs:label" content="H+" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasDbXref" content="KEGG:C00080" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:id" content="IMR:0200030" datatype="xsd:string"></span>h </span>37&#194;&#176;C. (nitrite/nitrate) <br />                                           production determined supernatants cultures Griess reaction kit <br />                                           (Sigma-Aldrich Corporation, St-Louis, MO) (37). <br />  <br />                               CFSE proliferation assay <br />                                           Proliferative capacity T cells assessed CFSE dilution assay Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                           immunized mice challenge wild type parasites (46). Age matched <br />                                           na&#195;&#175;ve mice served negative controls Ag-specific proliferation. Splenocytes                                           different groups mice isolated, incubated 5&#206;&#188;M CFSE (Molecular Probes/ <br />                                           Invitrogen) 10 min RPMI 1640 fetal calf serum (FCS) followed 5 min  <br />  <br />                                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                 Page 5 <br />  <br />  <br />                                            quenching ice-cold RPMI1640 plus 10% FCS subsequently washed thoroughly <br />                                            plating 96 tissue culture plates 2 &#195;&#8212; 105 cells  Cells cultured 5 <br />                                            days 37&#194;&#176;C 5% CO2 stimulation FTAg (50&#206;&#188;g/ml). Cells <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            harvested, washed blocked anti-CD16/32 (5&#206;&#188;g/ml) 20 min (4&#194;&#176;C), <br />                                            cell surface stained anti mouse CD3 APC-eFluor@780, anti mouse CD4 eFluor@450, <br />                                            anti mouse CD8a eFluor@605NC (eBioscience, USA) 30 min  1:200 dilution; <br />                                            4&#194;&#176;C). Cells acquired LSRII (BD Biosciences, USA) equipped 405, 488, 532, <br />                                            638 laser lines using DIVA 6.1.2 software. Data analyzed FlowJo <br />                                            software version 9.1.5. <br />  <br />                               Adoptive cell transfer <br />                                            Total T cells, CD4 CD8 T cells mice 16 weeks post-immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                            non-immunized na&#195;&#175;ve mice isolated transferred na&#195;&#175;ve mice. Purification                                            T cells performed Midi-MACS (Miltenyi Biotec, USA) using Pan-T <br />                                            cells, CD4 T cells CD8 T cells isolation kits, respectively recommended                                            manufacturer. 5 &#195;&#8212; 106 total T cells CD4 CD8 T cells transferred recipient mice <br />                                            24 hrs later groups mice infected L. donovani Wt parasites. purity <br />                                            isolated T cells population &gt; 95% observed flow cytometry. <br />  <br />                               Statistical analysis <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Statistical analysis differences means groups determined unpaired                                            tailed &#226;&#8364;&#732;Student t test&#226;&#8364;&#8482; using Graph Pad Prism 5.0 software. p value 0.05                                            considered significant p value 0.01 considered highly significant. <br />  <br />                               Results <br />                               Live attenuated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites disseminate visceral organs limited <br />                               persistence non pathogenic <br />                                            previously demonstrated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; mutant unable sustain 13 weeks <br />                                            post-infection defect overcome episomal expression p27 Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; cell <br />                                            line (38). dissect organ specific survival Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites, mice                                            injected intravenously stationary phase wild type (Wt) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; promastigotes                                            parasite burden measured spleen liver 4, 8 16 weeks post- <br />                                            infection (Figure 1A &amp; B). parasite burden significantly high spleen                                            liver Wt infected mice 16th week reflecting normal course infection. <br />                                             Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; mutants showed progressive decline 4 weeks post-infection                                            spleen liver. time points, 4 8 weeks post-infection, Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />                                            mice significantly (p&lt; 0.05) parasite burden compared Wt infected mice NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            organs (Figure 1A &amp; B). Interestingly, Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice 16th week,                                            parasites cleared organs, recover live parasites                                            serial dilutions cultured organ cell suspension mice. Similar results obtained <br />                                            confirmatory real-time PCR study using DNA spleens mice infected                                            Wt Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites (supplementary Table 1). Detection parasite specific <br />                                            minicircle DNA target indicated presence substantial number parasites Wt- <br />                                            infected (12 weeks) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected (12 weeks) mice.  20 weeks                                            infection Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217;, mice longer detectable parasites                                            significant parasite burden Wt-infected spleens, suggesting absence residual <br />                                            attenuated parasite persistence. Taken experiments suggested deletion                                            Ldp27 gene does affect visceralizing capacity cell line,                                            parasite growth severely impaired host organs leading clearance host. <br />  <br />  <br />  <br />  <br />                                                  J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                             Page 6 <br />  <br />  <br />                                           rule survival undetectable Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; mutant parasites visceral organs <br />                                           20 weeks post-infection, treated Wt Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite infected mice                                           Dexamethasone (DXM), known immune-suppressor allow proliferation residual <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           parasites. Wt-infected group, treatment DXM enhances parasite growth                                           spleen (Figure 1C) liver (data shown) 20 weeks 25 weeks infection.                                           Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice 20 weeks post-infection, 2 12 (16%) mice showed                                           low number parasites spleen liver.  25 weeks post- <br />                                           infection, DXM treatment did observe Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites                                           spleen, liver bone marrow. observations confirm Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; safe                                           immunogen does persist long term. <br />  <br />                                           ensure Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; cause pathogenesis analyzed histopathology                                           liver. Stained liver sections (Figure 1D) showed initially (6 weeks post infection) <br />                                           Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites generated inflammatory response resulting development                                           inflammatory foci. Unlike Wt-infected mouse liver, inflammatory foci                                           devoid parasites Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice.  later stage infection (16 <br />                                           weeks post-infection) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mouse liver completely free                                           inflammatory foci liver cells showed normal morphology. contrary                                           wild type L. donovani infected mouse liver, inflammatory foci, <br />                                           foci free parasites. observations confirm Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                           causes initial mild pathogenesis host liver, eventually host clears NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           parasite restores normal architecture liver tissue. <br />  <br />                               Immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; protects challenge virulent L. donovani <br />                                           determine protective efficacy Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization, na&#195;&#175;ve BALB/c mice                                           immunized Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites saline intravenous injection. weeks <br />                                           post-immunization mice challenged wild type L. donovani parasites                                           assessment parasite burden spleens livers time points post- <br />                                           challenge, measured limiting dilution. results showed immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                           significantly reduces liver spleen parasite burden 4, 8 12 weeks post-challenge <br />                                           compared non-immunized mice group (Figure 2A B). 12 weeks post- <br />                                           challenge, immunized mice showed significant protection having 2.5 log 4 log <br />                                           fold reduction parasite number liver spleen respectively compared non- <br />                                           immunized mice (Figure 2A &amp; B). Non-immunized infected mice showed significant <br />                                           splenomegally compared immunized infected mice (data shown). evaluate                                           ability Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization confer long-term protection, mice challenged                                           virulent L. donovani parasites 20 weeks following Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization, parasite <br />                                           load evaluated 12 weeks post-challenge (Fig 2C). significant reduction                                           parasite burden spleen liver mice challenged 20 weeks post-immunization <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           compared na&#195;&#175;ve challenged mice (Fig. 2C). reduction parasite burden                                           20 weeks post-immunization group (2 log fold spleen 1.5 log fold liver) <br />                                           12 week immunized group (4 log fold spleen 2.5 log fold liver, <br />                                           compare data Figure 2A &amp;B Figure 2C). Overall data suggest Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                           immunization confers significant sustained protection 20 weeks post-immunization. <br />  <br />                               Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization induces mixed pro-inflammatory anti-inflammatory cytokine <br />                               response virulent challenge <br />                                           characterize immune response induced live attenuated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites,                                           analyzed antigen-specific cytokine secretion splenocytes na&#195;&#175;ve, immunized, non- <br />                                           immunized challenged immunized challenged mice. significant induction <br />                                           Leishmania antigen specific IFN&#206;&#179; 12p70 secretion splenocyte culture <br />                                           supernatants 12 weeks post-immunized mice (Figure 3). IFN&#206;&#179; TNF&#206;&#177;  <br />  <br />                                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                              Page 7 <br />  <br />  <br />                                           induced 20 weeks post-immunized mice (Figure 3). Interestingly, following 3 weeks                                           challenge wild type L. donovani parasites, 12 weeks post-immunized mice showed <br />                                           significantly enhanced IFN&#206;&#179;, TNF&#206;&#177; 12 secretion 20 weeks post-immunized <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           mice showed significantly enhanced IFN&#206;&#179; 12, TNF&#206;&#177; secretion compared                                           non-immunized challenged mice. 12 weeks post-immunized challenged mice                                           significant induction anti inflammatory cytokines like 10, 4 13 <br />                                           compared na&#195;&#175;ve challenged. significant induction 10 secretion <br />                                           20 weeks post-immunized mice immunized challenged mice compared non- <br />                                           immunized challenged mice; difference levels 4 13 20 <br />                                           week immunized challenged mice. Overall results suggest Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite <br />                                           immunization primes selective long-term mixed pro anti-inflammatory immune <br />                                           response wild type parasites. <br />  <br />                               Resistance infection induced Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization associated induction                               Nitric Oxide splenocytes <br />                                           pro-inflammatory cytokines activate macrophages induce production. <br />                                           macrophage derived effector molecules crucial control                                           intracellular Leishmania infections (47). significant Leishmania antigen <br />                                           specific nitrite production observed 12 weeks 20 weeks post- <br />                                           immunized mice compared non-immunized mice splenocytes (Figure 4).                                           greater observed Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice wild type L. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           donovani challenge compared na&#195;&#175;ve challenged 12 20 weeks post-immunized <br />                                           mice (Figure 4). Interestingly induction nitrite concentration similar challenged <br />                                           animals immunized 12 20 weeks. Overall, sustained nitrite secretion level                                           splenocytes indicates pro-inflammatory cytokine dominating milieu immunized mouse <br />                                           spleens turn favors host clearing parasites. <br />  <br />                               Immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; induces sustained level Ag-specific T cell proliferation <br />                               response <br />                                           Impairment cell mediated immune response hallmark active VL humans                                           animals (48). Restoration antigen specific immune response crucial effective <br />                                           vaccine induced immunity. investigate proliferative potential reencounter                                           Leishmania antigen, spleen cells isolated na&#195;&#175;ve; na&#195;&#175;ve challenged, 20 weeks post- <br />                                           immunized immunized challenged mice. Splenocytes CFSE labeled stimulated <br />                                           vitro FTAg medium  5 days Ag stimulation, cells stained <br />                                           anti-CD3, anti-CD4 anti CD8 antibodies, CFSE profile analyzed                                           flow-cytometer (Figure 5A). FlowJo analysis showed CD3+ T cells including <br />                                           CD4 CD8 isolated mice immunized Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; significantly higher <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           proliferative capacity response Leishmania FTAg antigen compared T cells isolated <br />                                           na&#195;&#175;ve mice (Figure 5B).  T cells isolated mice immunized challenged <br />                                           virulent L. donovani parasites significantly (p&lt; 0.05) higher proliferative capacity <br />                                           na&#195;&#175;ve challenged group (Figure 5B). significant proliferative capacity T cells <br />                                           20 weeks post-immunized mice, suggests derived                                           memory response. <br />  <br />                               Induction multifunctional antigen experienced Th1 effector cells correlates                               Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; induced immunity <br />                                           Having shown immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite establishes stable, long- <br />                                           lived immunological protection wild type Leishmania parasite, subsequently <br />                                           characterized phenotype cytokine production antigen experienced effector <br />                                           memory T cells CD44HI/CCR7Low 20 weeks post-immunized animals (49&#226;&#8364;&#8220;50). Using <br />                                           intracellular FACS staining, antigen experienced CD4 CD8 T cells gated based  <br />                                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                         Page 8 <br />  <br />  <br />                                         surface expression CD44 CCR7 (Figure 6A). CD44HI/CCR7Low cells                                         separated seven distinct subpopulations based production IFN&#206;&#179;, TNF&#206;&#177;                                         2 combination pool effector memory T cells (Figure 6A). results <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         showed 20 weeks post-immunization, CD4 T cells, IFN&#206;&#179; single cytokine secreting cells <br />                                         dominating substantial number single 2 TNF&#206;&#177;+ producing                                         double IFN&#206;&#179;+ 2+ IFN&#206;&#179;+ TNF&#206;&#177;+ producing cells (Figure 6B). CD8 T cells, <br />                                         IFN&#206;&#179;+ cells dominating, significant number 2 TNF&#206;&#177;+ <br />                                         single producing cells double cytokine producing IFN&#206;&#179; 2+, IFN&#206;&#179;+TNF&#206;&#177;+, <br />                                         TNF&#206;&#177; 2+ triple cytokines producing IFN&#206;&#179;+TNF&#206;&#177; 2+ cells (Figure 6C).                                         importantly CD8 T cell compartment higher percentage double triple <br />                                         cytokine producing cells CD4 T cells compartment (Figure 6C vs Figure 6B). <br />  <br />                                         Having shown Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization induces long-term immune response <br />                                         characterized high level multifunctional CD4 CD8 T cells, characterized                                         nature immune response challenge wild type parasite. CD4 CD8 <br />                                         T cells spleens 12 weeks 20 weeks post-immunized challenged mice, <br />                                         IFN&#206;&#179; cytokine secreting cells significantly higher non-immunized <br />                                         challenged mice (Figure 7A&#226;&#8364;&#8220;D). addition, significantly higher percentage double                                         triple cytokine producing CD4 (Figure 7A &amp; B) CD8 (Figure 7C &amp; D) T cells                                         observed cytokines 12 weeks 20 weeks post-immunized                                         challenged mice compared non-immunized challenged mice. Particularly, CD4 T cells <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         IFN&#206;&#179;+ 2+, IFN&#206;&#179;+ TNF&#206;&#177;+ IFN&#206;&#179;+ 2+ TNF&#206;&#177;+ producing cells significantly <br />                                         higher 12 weeks post-immunized challenged mice. Similarly, 20 weeks <br />                                         immunized-challenged mice TNF&#206;&#177;+ 2+ IFN&#206;&#179;+ 2+ TNF&#206;&#177;+ cells higher <br />                                         compared non-immunized challenged mice. Albeit percentage cells                                         smaller compared 12 weeks post-immunized challenged mice. Interestingly, 20 <br />                                         week immunized mice, percentage double triple cytokine producing CD8 T <br />                                         cells higher compared CD4 T cells similar results observed immunized mice <br />                                         challenge. Overall results indicate Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice induce                                         strong antigen experienced effector memory T cell mediated immune response 20 <br />                                         weeks post-immunization time point majority mice cleared Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                         parasite. <br />  <br />                                         quantified antigen experienced CD4 CD8 T cells produce 10, crucial <br />                                         anti-inflammatory cytokine pathogenesis VL (16, 37, 51). antigen stimulated <br />                                         CD4 CD8 T cells spleen, IFN&#206;&#179;/ 10 ratio significantly higher                                         12ws immunized mice challenge compared non-immunized challenged mice (Figure <br />                                         8A). results indicate increased IFN&#206;&#179; secretion simultaneously decreased <br />                                         10 production antigen experienced CD4 CD8 T cells results strong Th1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         response translate protective immunity. addition 10 shown                                         critical immune-regulatory molecule necessary shape amplitude immune <br />                                         response prevent infection associated lesions (15, 52). Particularly, IFN&#206;&#179;                                         10 coproducing cells play important role prevent collateral tissue damage                                         extensive inflammatory cytokines (52). analyzed percentage IFN&#206;&#179;                                         10 coproducing antigen experienced CD4 CD8 T cells. mice challenged <br />                                         12ws post-immunization significantly higher percentage CD4                                         CD8 T cells positive IFN&#206;&#179; 10 compared na&#195;&#175;ve challenged mice <br />                                         (Figure 8B). Interestingly, percentage IFN&#206;&#179; 10 coproducing CD8 T cells                                         significantly higher coproducing CD4 T cells. Overall data clearly indicate <br />                                         Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization induces host protective cell mediated controlled <br />                                         proinflammatory immune response challenge wild type infection. <br />  <br />  <br />  <br />  <br />                                              J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                              Page 9 <br />  <br />  <br />                               Adoptive transfer isolated T cells Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice confers protection                               recipient mice <br />                                           confirm T cell mediated immunity sufficient protect wild type parasite <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           infection, performed adoptive transfer T cells. recipient mice infected                                           wild type parasites 10 weeks parasite load measured. Mice received T cells <br />                                           immunized mice showed significant reduction parasite burden compared                                           recipients T cells non-immunized mice. 4 log fold, 2 log fold 3.5 log <br />                                           fold reduction parasite burden spleens recipients Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized total T <br />                                           cells, CD4 T cells CD8 T cells respectively compared mice receiving non-immunized <br />                                           T cells (Figure 9). results clearly indicate attenuated parasite induced immunity                                           T cell mediated immunity CD4 CD8 T cells major effector T-cell <br />                                           populations important controlling parasite burden immunized mice. <br />  <br />                               Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization cross protects mice challenge Leishmania <br />                               species <br />                                           investigated immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; provide protection <br />                                           heterologous species Leishmania. Mice immunized   v.) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites <br />                                           12 weeks infected  footpad) L. major L. braziliensis. na&#195;&#175;ve <br />                                           mice infected L. major started developing progressive lesions 3 weeks post- <br />                                           challenge weeks post challenge developed large swollen footpad NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           lesions. contrary, Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice developed significantly smaller lesions <br />                                           compared na&#195;&#175;ve mice did continue swell (Figure 10A). immune- <br />                                           challenged mice showed significantly lower parasite burden footpads                                           lymph nodes compared na&#195;&#175;ve challenged mice (Figure 10B). Similarly                                           significantly reduced footpad swelling compared non-immunized mice Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                           immunized mice infection L. braziliensis, (Figure 10C). parasite burden                                           footpad draining lymph nodes significantly reduced immunized mice <br />                                           compared non-immunized mice (Fig. 10D). results suggest immunization live <br />                                           attenuated L. donovani parasites control parasitemia non visceralizing Leishmania <br />                                           infections. <br />  <br />                               Induction humoral response immunized mice <br />                                           specific evidence role Leishmania specific antibodies                                           determining outcome VL (53), dominance immunoglobulin subtype                                           predict outcome immune response vivo. Mouse sera assessed L. <br />                                           donovani specific IgG1 IgG2 isotypes, surrogate markers Th2 Th1 CD4 T cell <br />                                           differentiation respectively. Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice levels IgG2a IgG1                                           significantly different 8 weeks post infection.  IgG2a levels NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           progressively higher 12 16 weeks post-immunization groups mice (Figure S1A), <br />                                           correlated clearance Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites visceral organs (Fig. <br />                                           1AB). contrary mice infected Wt parasites, IgG2a/ IgG1 ratio lower, <br />                                           suggesting Th2 type immune response correlates disease progression                                           evident increased parasite burden (Figure 2AB). Interestingly, 20 weeks post- <br />                                           immunized challenged mice IgG2a/ IgG1 ratio significantly higher non- <br />                                           immunized challenged mice, suggesting host protective Th1 type immune response <br />                                           (Figure S1B). increased serum IgG2a levels observed immunized challenged <br />                                           mice correlate increased Th1 response. <br />  <br />                               Discussion <br />                                           Leishmania infection, individuals recover natural infection protected                                           reinfection develop life-long protection, suggesting infection prerequisite <br />  <br />                                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                            Page 10 <br />  <br />  <br />                                         immunological memory. genetically altered live-attenuated parasites controlled <br />                                         infectivity achieve immunological memory (37). addition, live attenuated <br />                                         parasites provide broad spectrum parasite antigens generate diverse antigen <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         specific memory immune response important protection infection. Live <br />                                         attenuated vaccination old widely accepted method broad spectrum                                         diseases like bacille Calmette-Guerin (BCG), polio vaccine, small pox, (24&#226;&#8364;&#8220;25).                                         study evaluated safety potency Leishmania live attenuated vaccine candidate, <br />                                         Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite homologous heterologous Leishmania species. observed <br />                                         host protection correlates induction Leishmania antigen specific cell <br />                                         mediated immune response. <br />  <br />                                         Safety live attenuated parasites vaccine essential parasites                                         regain virulence used human immunogens. tested Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                         parasites virulence mice. Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites reduced growth                                         promastigote stage  growth attenuated intracellular amastigote <br />                                         stage. parasites visceralize spleen liver mice cleared 20 <br />                                         weeks infection demonstrated absence parasite immune-suppressed <br />                                         mice. weeks immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite mice recruit infiltrating <br />                                         mononuclear cells form foci liver similar wild type infection.                                          foci lack parasites unlike wild type infection induced foci. Furthermore, 16 weeks post- <br />                                         immunization liver cell morphology returns normal similar uninfected <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         condition. suggesting Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites safe illicit host response <br />                                         causing pathogenesis. <br />  <br />                                         efficacy Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites immunogens confirmed significant parasite <br />                                         control immunized mice infection early late stages immunization.                                         established literature VL control parasitemia correlated                                         induction pro anti-inflammatory cytokine response (54&#226;&#8364;&#8220;55). correlation <br />                                         observed using Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites immunogens indicated significant enhanced <br />                                         secretion pro-inflammatory cytokines like IFN&#206;&#179;, TNF&#206;&#177; 12 significant <br />                                         induction anti-inflammatory cytokines like 10, 4 13.                                          balance pro-inflammatory anti-inflammatory cytokines avoid tissue <br />                                         injury. Recent studies suggested exacerbated response infections result                                         deleterious lesion extensive tissue damage, 10 prevents development                                         immuno-pathological tissue damage (15).  lack liver tissue damage                                         absence splenomegaly live attenuated parasite immunized mice outcome <br />                                         induction 10 secretion Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite balancing effect extensive <br />                                         pro-inflammatory cytokines IFN&#206;&#179;. addition, 4 13                                         shown crucial clearance L. donovani parasite liver spleen (56&#226;&#8364;&#8220;58). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          enhanced 4 13 levels observed early stage Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                         parasite immunization study important development hepatic <br />                                         granuloma maturation leishmaniacidal activity resulting enhanced production <br />                                         turn results significant reduction parasite visceral organs. Taken                                         results clearly suggest Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites induce mixed Th1 Th2 response <br />                                         causing tissue damage control parasite burden enhancing                                         leishmaniacidal activity. <br />  <br />                                         mice, vaccine induced T cell response shown correlate protection                                         Leishmaniasis (37, 59&#226;&#8364;&#8220;61).  analyzed CD4 CD8 T cells CD44HI/ <br />                                         CCR7Low populations represent antigen experienced effector memory T cells (61&#226;&#8364;&#8220;62)                                         determine correlates immune protection Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites. current study,                                         Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunization induced significantly high frequency antigen experienced CD4 <br />                                         CD8 T cells detected 20 weeks post-immunization  <br />  <br />                                              J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                            Page 11 <br />  <br />  <br />                                         conferred significant level protection. addition, significant level Ag <br />                                         specific T cell recall response indicated T cell proliferation 20 weeks post- <br />                                         immunization absence parasite persistence suggesting generation Ag-specific <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         memory cells. IFN-&#206;&#179; TNF-&#206;&#177; major cytokines involved clearance                                         intracellular pathogens like Leishmania, multifunctional cytokine producing cells                                         effective single cytokine secretory cells (37, 46, 61, 63). current <br />                                         study immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; increased percent Leishmania specific CD4                                         CD8 cells expressing Th1 cytokines (IFN&#206;&#179;, TNF&#206;&#177; 2) single multiple <br />                                         combinations response wild type parasite challenge. Importantly IFN&#206;&#179;+ TNF&#206;&#177;+                                         major double cytokine producing cells Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized challenged mice <br />                                         observed protection L. major infections (60&#226;&#8364;&#8220;61). previous <br />                                         studies established CD8 T cells play potential role cure leishmaniasis <br />                                         particularly VL (5, 37, 64&#226;&#8364;&#8220;66). study observed significant <br />                                         numbers single multiple cytokine producing CD8 T cells immunized challenged <br />                                         mice confirming immunization live attenuated Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites, CD8 T cells <br />                                         play essential role host protection. Furthermore, significantly Leishmania antigen <br />                                         responsive CD8 T cells present immunized mice na&#195;&#175;ve mice. protective <br />                                         function cells derive cytokine secretion cytotoxic activity. <br />                                          time analyzed cytotoxic function cells                                         focus future studies. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         significantly increased IFN&#206;&#179;/ 10 ratio CD4 CD8 T cells                                         immunized infected mice compared non-immunized infected mice, suggesting <br />                                         polarization Th1 type cell development observed L. infantum infected <br />                                         mice immunization SIR2+/&#226;&#710;&#8217; (35).  production IFN&#206;&#179; 10                                         antigen experienced CD4 CD8 T cells immunized infected mice suggests                                         desirable balance immune response allowing brief parasite persistence facilitates <br />                                         protection causing host damage (37). production multiple <br />                                         cytokine producing effector memory T cells T cells producing IFN-&#206;&#179; IL10                                         immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites suggests used markers                                         immune correlates protection Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; vaccine candidate. <br />  <br />                                         debated persistence parasites pool central memory T cells                                         essential protective immunity reinfection Leishmania (67&#226;&#8364;&#8220;69). CL                                         reported  anti-Leishmania memory cells develop infection maintained <br />                                         absence parasites, quality memory cells maintained presence <br />                                         absence live parasites different (68, 70). studies showed strong <br />                                         recall cellular immune response persistence attenuated parasites                                         absence attenuated parasites.  observation short term <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         immunized mice higher level protection long term immunized mice suggests <br />                                         persistence pool effector cells rapidly respond infection                                         absence parasite persistence, serves source antigen, small <br />                                         pool central memory cells respond slowly infection transitioning effector <br />                                         memory cells eventually help controlling parasite burden. persistence <br />                                         parasite antigen antigen specific effector T cells probably effective                                         central memory cells  adoptive transfer experiments confirm generation                                         antigen specific CD4 CD8 T cells immunized mice confer protection <br />                                         infection wild type parasites. Future studies needed analyze type                                         T cells (potentially memory T cells) specific role live attenuated parasite <br />                                         immunization. <br />  <br />                                         Various Leishmania species different tissue tropism resulting different phenotypes. <br />                                         ideal Leishmania vaccine control Leishmania <br />  <br />  <br />                                              J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                                Page 12 <br />  <br />  <br />                                         infections. reports shown cross protection L. major <br />                                         infections using parasite lysates defined proteins L. donovani (71&#226;&#8364;&#8220;72). <br />                                         Additionally, L. donovani DNA vaccines L. infantum sterol 24-c-methyl-transferase <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         partial knock parasites induced strong protection L. mexicana L. major <br />                                         infections respectively (60, 73). Similarly, previous studies showed LdCen&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                         parasite immunized mice cross-protected L. braziliensis infection (37).                                         study Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized mice cross-protected L. major (CL) <br />                                         L. braziliensis (MCL) infections. studies suggest efficacy                                         vaccine candidate depend quality cellular immunity antigen <br />                                         conservation species.  possible develop Leishmania vaccines <br />                                         especially live attenuated parasites provide opportunity broad based <br />                                         antigen repertoire immune respond cross protect infections <br />                                         Leishmania species. <br />  <br />                                         Overall study established Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; live attenuated parasite potential <br />                                         vaccine candidate VL, CL MCL.  significant differences                                         host immunity depending mode primary infections like needle inoculums vs sand <br />                                         fly mediated infections. Particularly CL, reported vaccine induced <br />                                         immunity confers protection needle challenge fails protect mice sand <br />                                         fly mediated infection (69, 74). studies strongly suggest testing efficacy                                         Leishmania vaccines sand fly mediated infections. Recently developed NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         rodent VL model sand fly vector mediated transmission (75). Vector-transmission <br />                                         generated slower progression VL resembled chronicity disease following <br />                                         natural transmission field. slower progression disease relevant                                         evolution immunity infection pathogenesis.  slow progression                                         vector-initiated VL appropriate studies early immune events, parasite <br />                                         establishment, screening drugs vaccines. model allow test <br />                                         live attenuated vaccine candidates sand fly mediated L. donovani infections. <br />  <br />                                         summary, results demonstrate immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites provides                                         significant protection infection homologous heterologous species                                         Leishmania parasites. immunization induced antigen specific strong multifunctional <br />                                         CD4 CD8 T cells correlates immune protection. Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites elicit memory <br />                                         response presence absence parasite persistence antigen specific <br />                                         cell mediated immunity correlated robust generation humoral response.                                         Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites safe persist long time reducing                                         chance reversion wild type cause pathogenesis. Taken                                          studies strongly support Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; mutant parasite safe effective immunogen <br />                                         potential vaccine broad spectrum leishmaniasis. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Supplementary Material <br />                                         Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                         want thank Drs. Alain Debrabant, Sanjai Kumar Sreenivas Gannavaram critical review                                         manuscript. <br />  <br />                                         Source grants: funding studies provided intramural funds Critical Path initiative                                         Center Biologics Evaluation Research, Food Drug Administration, USA. <br />  <br />  <br />  <br />  <br />                                                J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                  Page 13 <br />  <br />  <br />                               References <br />                                         1. Desjeux P. Leishmaniasis: current situation new perspectives. Comp Immunol Microbiol Infect <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Dis. 2004; 27:305&#226;&#8364;&#8220;318. [PubMed: 15225981] <br />                                         2. Desjeux P. Human leishmaniases: epidemiology public health aspects. World Health Stat Q. <br />                                            1992; 45:267&#226;&#8364;&#8220;275. [PubMed: 1462660] <br />                                         3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances leishmaniasis. Lancet. 2005; <br />                                            366:1561&#226;&#8364;&#8220;1577. [PubMed: 16257344] <br />                                         4. Banuls AL, Bastien P, Pomares C, Arevalo J, Fisa R, Hide M. Clinical pleiomorphism human <br />                                            leishmaniases, special mention asymptomatic infection. Clin Microbiol Infect. 2011; <br />                                            17:1451&#226;&#8364;&#8220;1461. [PubMed: 21933304] <br />                                         5. Kaye PM, Aebischer T. Visceral leishmaniasis: immunology prospects vaccine. Clin <br />                                            Microbiol Infect. 2011; 17:1462&#226;&#8364;&#8220;1470. [PubMed: 21851483] <br />                                         6. Kaye P, Scott P. Leishmaniasis: complexity host-pathogen interface. Nat Rev Microbiol. <br />                                            2011; 9:604&#226;&#8364;&#8220;615. [PubMed: 21747391] <br />                                         7. Harhay MO, Olliaro PL, Costa DL, Costa CH. Urban parasitology: visceral leishmaniasis Brazil. <br />                                            Trends Parasitol. 2011; 27:403&#226;&#8364;&#8220;409. [PubMed: 21596622] <br />                                         8. Selvapandiyan  Dey R, Gannavaram S, Lakhal-Naouar  Duncan R, Salotra P, Nakhasi HL. <br />                                            Immunity visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med. <br />                                            2012; 2012:631460. [PubMed: 21912560] <br />                                         9. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, Johnson WD, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Carvalho EM. Interleukin-12 restores interferon-gamma production cytotoxic responses                                            visceral leishmaniasis. J Infect Dis. 1996; 173:1515&#226;&#8364;&#8220;1518. [PubMed: 8648233] <br />                                         10. Bacellar O, D&#226;&#8364;&#8482;Oliveira Jr, Jeronimo S, Carvalho EM. 10 12 main regulatory <br />                                              cytokines visceral leishmaniasis. Cytokine. 2000; 12:1228&#226;&#8364;&#8220;1231. [PubMed: 10930301] <br />                                         11. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. Neutralization 12 <br />                                              demonstrates existence discrete organ-specific phases control Leishmania <br />                                              donovani. Eur J Immunol. 1998; 28:669&#226;&#8364;&#8220;680. [PubMed: 9521077] <br />                                         12. Ghalib HW, Whittle JA, Kubin M, Hashim FA, Mel-Hassan  Grabstein KH, Trinchieri G, Reed <br />                                              SG. 12 enhances Th1-type responses human Leishmania donovani infections. J Immunol. <br />                                              1995; 154:4623&#226;&#8364;&#8220;4629. [PubMed: 7722314] <br />                                         13. Murray HW, Hariprashad J, Coffman RL. Behavior visceral Leishmania donovani                                              experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med. 1997; <br />                                              185:867&#226;&#8364;&#8220;874. [PubMed: 9120392] <br />                                         14. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, Coffman RL. Interleukin-10 <br />                                               10) experimental visceral leishmaniasis 10 receptor blockade immunotherapy. <br />                                              Infect Immun. 2002; 70:6284&#226;&#8364;&#8220;6293. [PubMed: 12379707] <br />                                         15. Mege JL, Meghari S, Honstettre  Capo C, Raoult D. faces interleukin 10 human <br />                                              infectious diseases. Lancet Infect Dis. 2006; 6:557&#226;&#8364;&#8220;569. [PubMed: 16931407] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         16. Nylen S, Sacks D. Interleukin-10 pathogenesis human visceral leishmaniasis. Trends <br />                                              Immunol. 2007; 28:378&#226;&#8364;&#8220;384. [PubMed: 17689290] <br />                                         17. Cummings  Tuladhar R, Satoskar AR. Cytokines STATs cutaneous visceral <br />                                              leishmaniasis. J Biomed Biotechnol. 2010; 2010:294389. [PubMed: 20300429] <br />                                         18. Silvestre R, Cordeiro-da-Silva  Ouaissi  Live attenuated Leishmania vaccines: potential <br />                                              strategic alternative. Arch Immunol Ther Exp (Warsz). 2008; 56:123&#226;&#8364;&#8220;126. [PubMed: 18373245] <br />                                         19. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress problems. Parasitology. <br />                                              2006; 133(Suppl):S87&#226;&#8364;&#8220;112. [PubMed: 17274851] <br />                                         20. Modabber F. Vaccines leishmaniasis. Ann Trop Med Parasitol. 1995; 89(Suppl 1):83&#226;&#8364;&#8220;88. <br />                                              [PubMed: 8745930] <br />                                         21. Haldar JP, Ghose S, Saha KC, Ghose AC. Cell-mediated immune response Indian kala-azar                                              post-kala-azar dermal leishmaniasis. Infect Immun. 1983; 42:702&#226;&#8364;&#8220;707. [PubMed: 6642649] <br />                                         22. Kamil AA, Khalil EA, Musa  Modabber F, Mukhtar MM, Ibrahim  Zijlstra EE, Sacks D, <br />                                              Smith PG, Zicker F, El-Hassan  Alum-precipitated autoclaved Leishmania major plus bacille <br />                                              Calmette-Guerrin, candidate vaccine visceral leishmaniasis: safety, skin-delayed type <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                   Page 14 <br />  <br />  <br />                                             hypersensitivity response dose finding healthy volunteers. Trans R Soc Trop Med Hyg. <br />                                             2003; 97:365&#226;&#8364;&#8220;368. [PubMed: 15228261] <br />                                         23. Zijlstra EE, el-Hassan  Ismael  Ghalib HW. Endemic kala-azar eastern Sudan: NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             longitudinal study incidence clinical subclinical infection post-kala-azar dermal <br />                                             leishmaniasis. J Trop Med Hyg. 1994; 51:826&#226;&#8364;&#8220;836. [PubMed: 7810819] <br />                                         24. Lauring  Jones JO, Andino R. Rationalizing development live attenuated virus vaccines. <br />                                             Nat Biotechnol. 2010; 28:573&#226;&#8364;&#8220;579. [PubMed: 20531338] <br />                                         25. Svenson S, Kallenius G, Pawlowski  Hamasur B. new tuberculosis vaccines. Hum <br />                                             Vaccin. 2010; 6:309&#226;&#8364;&#8220;317. [PubMed: 20372087] <br />                                         26. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lackner AA, Aye PP, Didier P, <br />                                             Huang D, Shao L, Wei H, Letvin NL, Frothingham R, Haynes BF, Chen ZW, Jacobs WR Jr. <br />                                             Efficacy safety live attenuated persistent rapidly cleared Mycobacterium tuberculosis <br />                                             vaccine candidates non-human primates. Vaccine. 2009; 27:4709&#226;&#8364;&#8220;4717. [PubMed: 19500524] <br />                                         27. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient <br />                                             mutants attenuated virulence mice potentiate Th1 response. J Immunol. 1998; <br />                                             161:6794&#226;&#8364;&#8220;6801. [PubMed: 9862710] <br />                                         28. Gorczynski RM. Immunization susceptible BALB/c mice Leishmania braziliensis.  <br />                                             Resistance induced using immunogen adherent nonadherent cells infected mice. Cell <br />                                             Immunol. 1985; 94:1&#226;&#8364;&#8220;10. [PubMed: 3160485] <br />                                         29. Daneshvar H, Coombs GH, Hagan P, Phillips RS. Leishmania mexicana Leishmania major: <br />                                             attenuation wild-type parasites vaccination attenuated lines. J Infect Dis. 2003; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             187:1662&#226;&#8364;&#8220;1668. [PubMed: 12721947] <br />                                         30. Kimsey PB, Theodos CM, Mitchen TK, Turco SJ, Titus RG. avirulent lipophosphoglycan- <br />                                             deficient Leishmania major clone induces CD4+ T cells protect susceptible BALB/c mice <br />                                             infection virulent L. major. Infect Immun. 1993; 61:5205&#226;&#8364;&#8220;5213. [PubMed: 7901166] <br />                                         31. Mitchell GF, Handman E, Spithill TW. Vaccination cutaneous leishmaniasis mice using <br />                                             nonpathogenic cloned promastigotes Leishmania major importance route injection. <br />                                             Aust J Exp Biol Med Sci. 1984; 62(Pt 2):145&#226;&#8364;&#8220;153. [PubMed: 6466205] <br />                                         32. Rivier D, Shah R, Bovay P, Mauel J. Vaccine development cutaneous leishmaniasis. <br />                                             Subcutaneous administration radioattenuated parasites protects CBA mice virulent <br />                                             Leishmania major challenge. Parasite Immunol. 1993; 15:75&#226;&#8364;&#8220;84. [PubMed: 8446467] <br />                                         33. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination phosphoglycan-deficient <br />                                             Leishmania major protects highly susceptible mice virulent challenge inducing                                             strong Th1 response. J Immunol. 2004; 172:3793&#226;&#8364;&#8220;3797. [PubMed: 15004184] <br />                                         34. Zhang WW, Matlashewski G. Characterization A2-A2rel gene cluster Leishmania <br />                                             donovani: involvement A2 visceralization infection. Mol Microbiol. 2001; 39:935&#226;&#8364;&#8220; <br />                                             948. [PubMed: 11251814] <br />                                         35. Silvestre R, Cordeiro-Da-Silva  Santarem N, Vergnes B, Sereno D, Ouaissi  SIR2-deficient <br />                                             Leishmania infantum induces defined IFN-gamma 10 pattern correlates protection. J <br />                                             Immunol. 2007; 179:3161&#226;&#8364;&#8220;3170. [PubMed: 17709531] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         36. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, Fillion  Singh AK, Olivier M, Ouellette <br />                                             M. Reduced infectivity Leishmania donovani biopterin transporter genetic mutant use <br />                                             attenuated strain vaccination. Infect Immun. 2002; 70:62&#226;&#8364;&#8220;68. [PubMed: 11748164] <br />                                         37. Selvapandiyan  Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication- <br />                                             deficient Leishmania donovani induces long lasting protective immunity visceral <br />                                             leishmaniasis. J Immunol. 2009; 183:1813&#226;&#8364;&#8220;1820. [PubMed: 19592661] <br />                                         38. Dey R, Meneses C, Salotra P, Kamhawi S, Nakhasi HL, Duncan R. Characterization                                             Leishmania stage-specific mitochondrial membrane protein enhances activity                                             cytochrome c oxidase role virulence. Mol Microbiol. 2010; 77:399&#226;&#8364;&#8220;414. [PubMed: <br />                                             20497506] <br />                                         39. Selvapandiyan  Duncan R, Debrabant  Bertholet S, Sreenivas G, Negi NS, Salotra P, Nakhasi <br />                                             HL. Expression mutant form Leishmania donovani centrin reduces growth                                             parasite. J Biol Chem. 2001; 276:43253&#226;&#8364;&#8220;43261. [PubMed: 11544261] <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                 Page 15 <br />  <br />  <br />                                         40. Debrabant  Joshi MB, Pimenta PFP, Dwyer DM. Generation Leishmania donovani axenic <br />                                             amastigotes: growth biological characteristics. Intl J Parasitology. 2004; 34:205&#226;&#8364;&#8220;217. <br />                                         41. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             control Leishmania major persistence immunity. Nature. 2002; 420:502&#226;&#8364;&#8220;507. [PubMed: <br />                                             12466842] <br />                                         42. Selvapandiyan  Duncan R, Mendez J, Kumar R, Salotra P, Cardo LJ, Nakhasi HL. Leishmania <br />                                             minicircle DNA footprint assay sensitive detection rapid speciation clinical isolates. <br />                                             Transfusion. 2008; 48:1787&#226;&#8364;&#8220;1798. [PubMed: 18564397] <br />                                         43. Rousseau D, Suffia  Ferrua B, Philip P, Le Fichoux Y, Kubar JL. Prolonged administration                                             dexamethasone induces limited reactivation visceral leishmaniasis chronically infected <br />                                             BALB/c mice. Eur Cytokine Netw. 1998; 9:655&#226;&#8364;&#8220;661. [PubMed: 9889410] <br />                                         44. Buxbaum LU, Denise H, Coombs GH, Alexander J, Mottram JC, Scott P. Cysteine protease B                                             Leishmania mexicana inhibits host Th1 responses protective immunity. J Immunol. 2003; <br />                                             171:3711&#226;&#8364;&#8220;3717. [PubMed: 14500670] <br />                                         45. Dey R, Sarkar  Majumder N, Bhattacharyya Majumdar S, Roychoudhury K, Bhattacharyya S, <br />                                             Roy S, Majumdar S. Regulation impaired protein kinase C signaling chemokines murine <br />                                             macrophages visceral leishmaniasis. Infect Immun. 2005; 73:8334&#226;&#8364;&#8220;8344. [PubMed: <br />                                             16299331] <br />                                         46. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands  <br />                                             Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity <br />                                             characterized multifunctional CD4 memory T cells. J Immunol. 2009; 182:8047&#226;&#8364;&#8220;8055. <br />                                             [PubMed: 19494330] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         47. Wei XQ  Charles G, Smith  Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. <br />                                             Altered immune responses mice lacking inducible nitric oxide synthase. Nature. 1995; 375:408&#226;&#8364;&#8220; <br />                                             411. [PubMed: 7539113] <br />                                         48. Carvalho EM, Teixeira RS, Johnson WD Jr. Cell-mediated immunity American visceral <br />                                             leishmaniasis: reversible immunosuppression acute infection. Infect Immun. 1981; 33:498&#226;&#8364;&#8220; <br />                                             500. [PubMed: 7275314] <br />                                         49. Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanley C, Orme IM. Phenotypic <span id='am-17' about='obo:IAO_0000115' typeof='owl:Thing'>definition</span> <br />                                             effector memory T-lymphocyte subsets mice chronically infected Mycobacterium <br />                                             tuberculosis. Clin Vaccine Immunol. 2010; 17:618&#226;&#8364;&#8220;625. [PubMed: 20107011] <br />                                         50. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, <br />                                             Ahmed R. Lineage relationship protective immunity memory CD8 T cell subsets. Nat <br />                                             Immunol. 2003; 4:225&#226;&#8364;&#8220;234. [PubMed: 12563257] <br />                                         51. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation 10 <br />                                             mRNA T cells distinct CD4+CD25+ (Foxp3) regulatory T cells human visceral <br />                                             leishmaniasis. J Exp Med. 2007; 204:805&#226;&#8364;&#8220;817. [PubMed: 17389235] <br />                                         52. Flores-Garcia Y, Rosales-Encina JL, Satoskar AR, Talamas-Rohana P. 10-IFN-gamma double <br />                                             producers CD4+ T cells induced immunization amastigote stage specific derived <br />                                             recombinant protein Trypanosoma cruzi. Int J Biol Sci. 2011; 7:1093&#226;&#8364;&#8220;1100. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             21927578] <br />                                         53. Bhowmick S, Mazumdar T, Ali N. Vaccination route induces transforming growth factor beta <br />                                             production fails elicit protective immunity Leishmania donovani infection. Infect <br />                                             Immun. 2009; 77:1514&#226;&#8364;&#8220;1523. [PubMed: 19168736] <br />                                         54. Alexander J, Carter KC, Al-Fasi N, Satoskar  Brombacher F. Endogenous 4 necessary                                             effective drug therapy visceral leishmaniasis. Eur J Immunol. 2000; 30:2935&#226;&#8364;&#8220;2943. <br />                                             [PubMed: 11069076] <br />                                         55. Bruhn KW, Birnbaum R, Haskell J, Vanchinathan V, Greger S, Narayan R, Chang PL, Tran TA, <br />                                             Hickerson SM, Beverley SM, Wilson  Craft N. Killed metabolically active Leishmania <br />                                             infantum novel cell vaccine visceral leishmaniasis. Clin Vaccine Immunol. 2012; <br />                                             19:490&#226;&#8364;&#8220;498. [PubMed: 22323556] <br />                                         56. McFarlane E, Carter KC, McKenzie  Kaye PM, Brombacher F, Alexander J. Endogenous <br />                                             13 plays crucial role liver granuloma maturation Leishmania donovani infection, <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                                  Page 16 <br />  <br />  <br />                                             independent 4Ralpha-responsive macrophages neutrophils. J Infect Dis. 2011; 204:36&#226;&#8364;&#8220; <br />                                             43. [PubMed: 21628656] <br />                                         57. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM. interleukin-4  4) 4 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             receptor alpha signaling contribute development hepatic granulomas optimal <br />                                             antileishmanial activity. Infect Immun. 2003; 71:4804&#226;&#8364;&#8220;4807. [PubMed: 12874364] <br />                                         58. Murray HW, Tsai CW, Liu J, Ma X. Visceral Leishmania donovani infection interleukin-13&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                             mice. Infect Immun. 2006; 74:2487&#226;&#8364;&#8220;2490. [PubMed: 16552085] <br />                                         59. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, recombinant polyprotein <br />                                             vaccine protects visceral Leishmaniasis elicitation CD4+ T cells. Infect Immun. <br />                                             2007; 75:4648&#226;&#8364;&#8220;4654. [PubMed: 17606603] <br />                                         60. Goto Y, Bhatia  Raman VS, Vidal SE, Bertholet S, Coler RN, Howard RF, Reed SG. <br />                                             Leishmania infantum sterol 24-c-methyltransferase formulated MPL-SE induces cross- <br />                                             protection L. major infection. Vaccine. 2009; 27:2884&#226;&#8364;&#8220;2890. [PubMed: 19428898] <br />                                         61. Darrah PA, Patel DT, Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, <br />                                             Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define correlate                                             vaccine-mediated protection Leishmania major. Nat Med. 2007; 13:843&#226;&#8364;&#8220;850. [PubMed: <br />                                             17558415] <br />                                         62. Kaveh DA V, Bachy S, Hewinson RG, Hogarth PJ. Systemic BCG immunization induces <br />                                             persistent lung mucosal multifunctional CD4 T(EM) cells expand following virulent <br />                                             mycobacterial challenge. PLoS  2011; 6:e21566. [PubMed: 21720558] <br />                                         63. Bogdan C, Moll H, Solbach W, Rollinghoff M. Tumor necrosis factor-alpha combination NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             interferon-gamma, interleukin 4 activates murine macrophages elimination                                             Leishmania major amastigotes. Eur J Immunol. 1990; 20:1131&#226;&#8364;&#8220;1135. [PubMed: 2113475] <br />                                         64. Joshi T, Rodriguez S, Perovic V, Cockburn IA, Stager S. B7-H1 blockade increases survival                                             dysfunctional CD8(+) T cells confers protection Leishmania donovani infections. <br />                                             PLoS Pathog. 2009; 5:e1000431. [PubMed: 19436710] <br />                                         65. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, Udey MC, Sacks D. CD8+ T <br />                                             cells required primary immunity C57BL/6 mice following low-dose, intradermal <br />                                             challenge Leishmania major. J Immunol. 2002; 168:3992&#226;&#8364;&#8220;4000. [PubMed: 11937556] <br />                                         66. Stager S, Rafati S. CD8(+) T cells leishmania infections: friends foes? Immunol. 2012; <br />                                             3:5. [PubMed: 22566891] <br />                                         67. Seder RA, Sacks DL. Memory need reminding. Nat Med. 2004; 10:1045&#226;&#8364;&#8220;1047. [PubMed: <br />                                             15459703] <br />                                         68. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity                                             Leishmania major absence persistent parasites. Nat Med. 2004; 10:1104&#226;&#8364;&#8220;1110. [PubMed: <br />                                             15448686] <br />                                         69. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission                                             leishmania abrogates vaccine-induced protective immunity. PLoS Pathog. 2009; 5:e1000484. <br />                                             [PubMed: 19543375] <br />                                         70. Okwor  Uzonna J. Persistent parasites immunologic memory cutaneous leishmaniasis: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             implications vaccine designs vaccination strategies. Immunol Res. 2008; 41:123&#226;&#8364;&#8220;136. <br />                                             [PubMed: 18389179] <br />                                         71. Rachamim N, Jaffe CL. Pure protein Leishmania donovani protects mice                                             cutaneous visceral leishmaniasis. J Immunol. 1993; 150:2322&#226;&#8364;&#8220;2331. [PubMed: 8450215] <br />                                         72. Tonui WK, Titus RG. Cross-protection Leishmania donovani L. Braziliensis caused <br />                                             vaccination L. Major soluble promastigote exogenous antigens BALB/c mice. J <br />                                             Trop Med Hyg. 2007; 76:579&#226;&#8364;&#8220;584. [PubMed: 17360887] <br />                                         73. Aguilar  da Silva Zardo R, Paraguai Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut- <br />                                             Martin M, Garcia-Miss R, del M, Palatnik Sousa CB, Dumonteil E. Cross-protective efficacy                                             prophylactic Leishmania donovani DNA vaccine visceral cutaneous murine <br />                                             leishmaniasis. Infect Immun. 2005; 73:812&#226;&#8364;&#8220;819. [PubMed: 15664920] <br />                                         74. Rogers  Sizova OV, Ferguson MA, Nikolaev AV, Bates PA. Synthetic glycovaccine protects <br />                                             bite leishmania-infected sand flies. J Infect Dis. 2006; 194:512&#226;&#8364;&#8220;518. [PubMed: <br />                                             16845636] <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                            Page 17 <br />  <br />  <br />                                         75. Aslan H, Dey R, Meneses C, Castrovinci P, Jeronimo S, Oliva G, Fischer L, Duncan R, Nakhasi <br />                                             HL, Valenzuela J, Kamhawi S. New Model Progressive Visceral Leishmaniasis Hamsters <br />                                             Natural Transmission Bites Vector Sand Flies. J Infect Dis. 2012 press. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                          Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 1. <br />                                         Avirulent properties p27 knockout L. donovani (Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217;) parasite BALB/c mice. <br />                                         Survival wild type (Wt) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites Liver   Spleen (B) BALB/c <br />                                         mice. Mice infected Wt Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites, 4, 8 16 weeks (ws) post- <br />                                         infection (PI) parasite load infected mice measured. (C) Effect immunosuppressive <br />                                         drug Dexamethasone (DXM) infected mice. Parasite load measured spleen                                         mice infected Wt p27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite different weeks post-infection treated <br />                                         DXM. (D) Histopathology liver Wt Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice 6 weeks <br />                                         16 weeks post-infection. Black arrows pointing infection foci intra-cellular parasites. <br />                                         data presented representative independent experiments similar results <br />                                         4 mice group. Mean SEM group shown. *, p &lt; 0.05. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                       Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 2. <br />                                         Protection Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasite immunization L. donovani infection. Mice                                         immunized Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; parasites PBS, 12 weeks post-immunized mice <br />                                         challenged Wt parasites. Parasite number Liver   Spleen (B)                                         measured 4 weeks, 8 weeks 12 weeks post- infection. Mean SEM mice NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         group shown. (C) Long term effect immunization. 20 weeks post-immunized <br />                                         mice challenged Wt parasites 12 weeks infection parasite burden                                         determined. data representation independent experiments similar <br />                                         results 4- 5 mice group. Mean SEM group shown. PI, post- <br />                                         immunization; PC, post-challenge *, p &lt; 0.05 **, p &lt; 0.01. <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                       Page 20 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 3. <br />                                         Leishmania antigen stimulated cytokine profiles splenocyte culture supernatants NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         na&#195;&#175;ve, Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized (Imm), na&#195;&#175;ve challenged (Na&#195;&#175;ve Chal) Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; immunized <br />                                         challenged (Imm Chal) mice. 12 20 weeks post immunized mice challenged                                         wild type parasite 3 weeks post challenge mice euthanized (shown bar <br />                                         diagram) spleens collected. Concentration cytokines culture supernatants <br />                                         measured using multiplex mouse cytokine kit described Materials &amp; Methods <br />                                         section. data presented representative independent experiments similar <br />                                         results. Mean SEM group shown. *, p &lt; 0.05 **, p &lt; 0.01. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                         Page 21 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 4. <br />                                         Immunization Ldp27&#226;&#710;&#8217;/&#226;&#710;&#8217; induces Nitric Oxide   production splenocyte.                                         activity NOS2 indicated released nitrite antigen stimulated <br />                                         splenocytes supernatants (48 hrs) measured Griess reaction. data <br />                                         presented representative experiments similar results 4&#226;&#8364;&#8220;5 mice                                         group. Mean SEM mice group shown. PI, post- <br />                                         immunization; PC, post-challenge * p&lt; 0.05; ** p &lt; 0.01 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Immunol. Author manuscript; available PMC 2014 March 01. <br />                             Dey et al.                                                                                      Page 22 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 5. <br />                                         Proliferative capacity Ag-specific T cells 20 <br /> </body></html>